Abstract 367P
Background
Radiologically defined sarcopenia has been associated with adverse oncological outcomes, with CT imaging being an expedient tool for determining sarcopenia in cancer patients. The objective of this meta-analysis is to assess the association of sarcopenia defined on CT head and neck with survival in head and neck cancer patients.
Methods
Following a PROSPERO-registered protocol, three reviewers conducted a systematic review of the PubMed, Embase and Cochrane Library for observational studies that reported the presence of sarcopenia in association with mortality estimates. Two blinded reviewers extracted data and evaluated the quality of included studies using the Quality of Prognostic Studies tool and the Grading of Recommendations, Assessment, Development and Evaluations framework. A meta-analysis was conducted using maximally adjusted hazard ratios for mortality estimates and correlation coefficients. Heterogeneity was investigated using meta-regression and subgroup analyses.
Results
From 33 studies (9083 participants), sarcopenia was associated with poorer overall survival (HR, 2.09; 95% CI, 1.77 to 2.47; p = .01), disease-free survival (HR, 1.76; 95% CI, 1.38 to 2.24; p < .01) disease-specific survival (HR, 2.24; 95% CI, 1.82 to 3.67; p < .01), progression-free survival (HR, 2.24; 95% CI, 1.82 to 3.67; p < .01) and increased chemotherapy or radiotherapy toxicity (RR, 2.28; 95% CI, 1.31 to 3.95; p < .01). Overall survival was significantly poorer in studies with mean BMI <25 kg/m2 compared with studies with mean BMI ≥25 kg/m2. The observed association between sarcopenia and overall survival remained significant across different locations of cancer, treatment modality, tumor stages and geographical region, and did not differ between univariate and multivariate hazard ratios. Statistically significant correlations were observed between C3 and L3 cross-sectional area, skeletal muscle mass and skeletal muscle index.
Conclusions
Among patients with head and neck cancers, CT-defined sarcopenia was consistently associated with poorer survival and greater toxicity. Our findings are easily applicable in clinical practice, by measuring sarcopenia at the C3 vertebra on routine staging CT scans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract